Marché mondial du traitement d’Arnold-Chiari – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché du traitement Arnold-Chiari

Le marché mondial du traitement de la maladie d'Arnold-Chiari connaît une croissance plus rapide en raison de l'augmentation des cas de cette maladie. La malformation de Chiari I est un type courant et survient chez près de 0,5 à 3,5 % de la population générale, avec une légère prédominance féminine. L'évaluation par imagerie des malformations de Chiari varie.

Data Bridge Market Research analyse le taux de croissance du marché mondial du traitement Arnold-Chiari au cours de la période de prévision 2022-2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du traitement Arnold-Chiari

Définition du marché

Arnold-Chiari is the condition of structural defects form in the cerebellum, the important part of the brain that controls balance. Arnold-Chiari malformation can also result from the abnormally small skull or misshapen skull forcing downwards. The primary symptoms of Arnold-Chiari malformation are pain, vision problems, headache, balance and coordination problems, dizziness, and trouble swallowing. The medicines can be generally given to manage symptoms such as pain, followed by monitoring and surgery. 

Global Arnold-Chiari Treatment Market Dynamics

Drivers

• Increased Diagnostic Methods

The growing diagnostic methods are boosting the growth of the market. Tests such as magnetic resonance imaging (MRI), typically in a child or adult, ultrasound in utero, with fetal MRI assessment are performed for further characterization. Thus, all these tests are boosting the market growth.

• Increasing Incidence in Elderly Population

Myelofibrosis cases are mostly witnessed in the age group ≤ 40 years, 41−60 years, and > 60 years. The >60 years group saw the highest number of patients mostly around 10,275 in 2021 in the U.S. In 2021, the eligible treatment population of myelofibrosis accounted for 9,511 cases in the U.S. Thus, this elderly population with higher chances of getting this disease boosts the market growth.

Opportunities

• Rising R&D and New Drug Approvals

The unmet needs of patients suffering from myelofibrosis encourage manufacturers to innovate new solutions. The increasing investments in R&D activities to develop a precise treatment for myelofibrosis are anticipated to boost the industry's growth in the forecast period. The speedy technological advancements and ongoing clinical trials contribute to industry growth. Other factors such as improved healthcare sector, reimbursement policies, favorable government initiatives, busy lifestyles, and changing dietary patterns are also leading to industry growth.   

• Increasing Collaborations and Market Expansion

Some bulging companies operating in the market are Novartis, Pfizer, Takeda, Incyte, Bristol-Myers Squibb, and Teva. Collaborations for development, broader product portfolios, and regional expansion in developing markets are the major strategic undertakings of these market players to increase their market share. Thus, these factors are growing the market.

 Restraints/Challenges

• Lack of Awareness

The lack of awareness about these disorders and the unavailability of numerous awareness programs hamper the market growth. The available drugs have not shown disease-modifying activity and are still mostly inadequate for managing major unmet needs.

• High Cost

The huge expenditure associated with these agents hampers the market growth. The huge drug development and associated processes hamper the market's growth.

This global Arnold-Chiari treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Arnold-Chiari treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Arnold-Chiari Treatment Market Scope

The global Arnold-Chiari treatment market is segmented on the basis of type, treatment, diagnosis, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Type 1
• Type 2
• Type 3
• Type 4

Treatment

• Medical Treatment
• Surgical Treatment

Diagnosis

• X-Ray
• CT-Scan
• Sleep Study
• Swallowing Study
• Myleogram
• MRI

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Arnold-Chiari Treatment Market Regional Analysis/Insights

The global Arnold-Chiari treatment market is analyzed and market size insights and trends are provided by type, treatment, diagnosis, distribution channel and end-user as referenced above.

The major countries covered in the global Arnold-Chiari treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the global Arnold-Chiari treatment market throughout the forecasted period due to the increased prevalence of nutrients lacking maternal diet and genetic mutations.

North America dominates the market due to the presence of key manufacturers of the product, high research and development and healthcare expenditure, and skilled professionals in the region

La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché mondiales du traitement Arnold-Chiari

Le paysage concurrentiel du marché mondial du traitement Arnold-Chiari fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial du traitement Arnold-Chiari.

Les principaux acteurs opérant sur le marché mondial du traitement d'Arnold-Chiari comprennent :

• Pfizer Inc (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Fresenius Kabi AG (Allemagne)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Novartis SA (Suisse)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Société Bristol Myers Squibb (États-Unis)
• GSK Plc. (Royaume-Uni)
• Bayer AG (Allemagne)
• Sun Pharmaceutical Industries Ltd (Inde)

SKU-55608